René Galien

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases · 2021 · 333 citations · Full text

Medicine, Internal Medicine, Pharmacology +16

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology · 2013 · 234 citations · Full text

Life Sciences, Immunology, Pharmacology +12

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

Christel Menet, Stephen R. Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry · 2014 · 121 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology · 2017 · 80 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-<i>a</i>]pyridine Series of Autotaxin Inhibitors

Agnès Joncour, Nicolas Desroy, Christopher Housseman et al. · Journal of Medicinal Chemistry · 2017 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16